ZEALAND PHARMA/S (NASDAQ:ZEAL) has been assigned an average rating of “Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $31.00.
Several analysts have recently issued reports on the company. TheStreet cut ZEALAND PHARMA/S from a “c” rating to a “d+” rating in a report on Friday, August 16th. Morgan Stanley upped their price objective on ZEALAND PHARMA/S from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective (up from $29.00) on shares of ZEALAND PHARMA/S in a report on Thursday, August 15th. Finally, Zacks Investment Research cut ZEALAND PHARMA/S from a “buy” rating to a “hold” rating in a report on Saturday, July 27th.
A hedge fund recently raised its stake in ZEALAND PHARMA/S stock. Farallon Capital Management LLC boosted its stake in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) by 5.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,000,000 shares of the company’s stock after buying an additional 51,300 shares during the period. Farallon Capital Management LLC owned approximately 3.25% of ZEALAND PHARMA/S worth $21,550,000 at the end of the most recent quarter. 9.08% of the stock is owned by hedge funds and other institutional investors.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.10). The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $7.50 million. On average, analysts predict that ZEALAND PHARMA/S will post -2.22 EPS for the current fiscal year.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Recommended Story: How do candlesticks reflect price movement?
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.